About us

Our Mission

Contribute to the health of people everywhere through

the provision of specialized blood cells created by regenerative medicine technology.

We produce and supply the necessary amount of homogeneous and highly accurate “human blood cells” using regenerative medicine technology, which dramatically improves the efficiency of research on infectious diseases and the evaluation of efficacy and safety of pharmaceuticals and functional materials. We also sell evaluation kits and provide contracted evaluation services.

Company Profile

Name of company

MiCAN Technologies, Inc.


Head Office (Kyoto Research Institute) Kyoto-University Katsura Venture Plaza, 1-36 Goryo-ohara, Nishikyo-ku, Kyoto 615-8245 Japan
TEL: +81-75-381-3008
 Google map

Kobe Research Institute 6-3-7 Minatojima Minamicho, Chuo-ku, Kobe, Hyogo 650-0047 Japan Google map


Kazuo Miyazaki, Chief Executive Officer


July 2016



Business lineup

Provision (sales) of blood cell-like cells for research using regenerative medicine technologies Evaluation service for pharmaceutical development(contract service) using the above-stated blood cell-like cells Contract service of various tests using the above-stated blood cell-like cells based on alternative methods to animal testing

Our History

  • ALL

Accepted in the Support System for Venture Companies Solving Unmet Medical Needs of the Ministry of Economy, Trade and Industry

2016  July

Foundation(Chuo-ku, Tokyo)

2016  November

Awarded a grand prize of GLOBIS Venture Challenge

2017  October

Development of red blood-like cells for research of infectious diseases (Mpv cells, first product) with Kyoto University and Nagasaki University, patent application

2017  December

Started development of myeloid cells for research of viruses (Mylc cells, second product)

2018  February

Established a research and development base at Kyoto-University Katsura Venture Plaza

2018  July

Started release of red blood-like cells (prototype product of Mpv cells)

2018  August

Patent application for myeloid cells for research of viruses (Mylc cells, second product) with Osaka University and Kumamoto University

2018  September

Transferred the Headquarters to Kyoto-University Katsura Venture Plaza

2018  November

Adopted for the Economic Gardening Support Grant supported by KyotoIndustrial Support Organization 21

2018  December

Certified as Management of Wisdom by the Kyoto Chamber of Commerce and Industry

2019  March

Expanded the Headquarters and Laboratory

2019  April

Signed a collaborative research agreement on the development of culture medium with Nissui Pharmaceutical Co., Ltd.

2019  July

Started release of myeloid cells for research of viruses (prototype product)

2019  August

Raised \127,000,000 by allocation of shares to third parties including Osaka University Venture Capital Co., Ltd. (series A)

2020  April

Started collaborative research on corona virus using Mylc cells with Osaka University

2020  June

elected in Support for Improvement Research, Technology Development Project for Measures to Control Viral Infections, by AMED

2022  March

Won the Grand Prix in the Collaboration Category of the 2nd Wisdom-1 Grand Prix sponsored by the Kyoto Chamber of Commerce and Industry.

2022  March

Awarded “Real Tech Venture of the Year 2022” in the Growth category

2022  August

Adopted for the “Go-Tech Project” (R&D Support Project for Growth-oriented Small and Medium Enterprises)

2023  April

MyrcMAT Kit (for research), a kit for evaluation of thermogenic substances using immortalized myeloid cells (Mylc), is now available for testing.

2023  August

Raised 200 million yen through third-party allotment to real-tech funds and others (Series B)

2023  September

Selected for NEDO’s Deep Tech Startup Support Project PCA Phase (Practical Application R&D (late stage))

Our Team

  • Kazuo Miyazaki
    Chief Executive Officer
    Kazuo Miyazaki
  • Kazuhisa Fushihara
    Chief Operating Officer / Chief Financial Officer
    Kazuhisa Fushihara
  • Yasuchika Wakayama
    Outside board member
    Yasuchika Wakayama
  • Outside board member
    Yuichi Oku
  • Yuichi Oku
    Corporate Auditor
    Masaki Mizoguchi


Please feel free to contact us.

We will conduct a brief interview with the person in charge and propose the best solution to solve your company’s issues.